Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

被引：0
|
作者：
Begoña Comin-Anduix
Yohan Lee
Jason Jalil
Alain Algazi
Pilar de la Rocha
Luis H Camacho
Viviana A Bozon
Cecile A Bulanhagui
Elisabeth Seja
Arturo Villanueva
Bradley R Straatsma
Antonio Gualberto
James S Economou
John A Glaspy
Jesus Gomez-Navarro
Antoni Ribas
机构：
[1] University of California Los Angeles (UCLA),Department of Surgery, Division of Surgical Oncology
[2] UCLA,Department of Human Genetics
[3] Oncology Consultants PA,Department of Medicine, Division of Hematology/Oncology
[4] Pfizer Global Research and Development (PGRD),Department of Ophthalmology
[5] UCLA,Department of Microbiology
[6] Jules Stein Eye Institute,Jonsson Comprehensive Cancer Center
[7] UCLA,undefined
[8] Immunology and Molecular Genetics,undefined
[9] UCLA,undefined
来源：
Journal of Translational Medicine | / 6卷
关键词：
Melanoma; Peripheral Blood Mononuclear Cell; ELISPOT Assay; Immune Monitoring; FoxP3 mRNA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
    Comin-Anduix, Begona
    Lee, Yohan
    Jalil, Jason
    Algazi, Alain
    de la Rocha, Pilar
    Camacho, Luis H.
    Bozon, Viviana A.
    Bulanhagui, Cecile A.
    Seja, Elisabeth
    Villanueva, Arturo
    Straatsma, Bradley R.
    Gualberto, Antonio
    Economou, James S.
    Glaspy, John A.
    Gomez-Navarro, Jesus
    Ribas, Antoni
    JOURNAL OF TRANSLATIONAL MEDICINE, 2008, 6 (1)
  • [2] Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
    Ribas, Antoni
    Hanson, Douglas C.
    Noe, Dennis A.
    Millham, Robert
    Guyot, Deborah J.
    Bernstein, Steven H.
    Canniff, Paul C.
    Sharma, Amarnath
    Gomez-Navarro, Jesus
    ONCOLOGIST, 2007, 12 (07): : 873 - 883
  • [3] Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    Hodi, F. Stephen
    Butler, Marcus
    Oble, Darryl A.
    Seiden, Michael V.
    Haluska, Frank G.
    Kruse, Andrea
    MacRae, Suzanne
    Nelson, Marybeth
    Canning, Christine
    Lowy, Israel
    Korman, Alan
    Lautz, David
    Russell, Sara
    Jaklitsch, Michael T.
    Ramaiya, Nikhil
    Chen, Teresa C.
    Neuberg, Donna
    Allison, James P.
    Mihm, Martin C.
    Dranoff, Glenn
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (08) : 3005 - 3010
  • [4] Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
    Eroglu, Zeynep
    Kim, Dae Won
    Wang, Xiaoyan
    Camacho, Luis H.
    Chmielowski, Bartosz
    Seja, Elizabeth
    Villanueva, Arturo
    Ruchalski, Kathleen
    Glaspy, John A.
    Kim, Kevin B.
    Hwu, Wen-Jen
    Ribas, Antoni
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (17) : 2689 - 2697
  • [5] What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
    Robert, Caroline
    Ghiringhelli, Francois
    ONCOLOGIST, 2009, 14 (08): : 848 - 861
  • [6] Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - A new cause of uveitis
    Robinson, MR
    Chan, CC
    Yang, JC
    Rubin, BI
    Gracia, GJ
    Sen, HN
    Csaky, KG
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : 478 - 479
  • [7] Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
    Tarhini, Ahmad A.
    Kirkwood, John M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (10) : 1583 - 1593
  • [8] Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    Hodi, FS
    Mihm, MC
    Soiffer, RJ
    Haluska, FG
    Butler, M
    Seiden, MV
    Davis, T
    Henry-Spires, R
    MacRae, S
    Willman, A
    Padera, R
    Jaklitsch, MT
    Shankar, S
    Chen, TC
    Korman, A
    Allison, JP
    Dranoff, G
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) : 4712 - 4717
  • [9] Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Phan, GQ
    Yang, JC
    Sherry, RM
    Hwu, P
    Topalian, SL
    Schwartzentruber, DJ
    Restifo, NP
    Haworth, LR
    Seipp, CA
    Freezer, LJ
    Morton, KE
    Mavroukakis, SA
    Duray, PH
    Steinberg, SM
    Allison, JP
    Davis, TA
    Rosenberg, SA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) : 8372 - 8377
  • [10] Immune Modulation in Melanoma and Advanced Cancer Therapy: Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 Monoclonal Antibodies
    Esper, Peg
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2009, 13 (05) : 547 - 554
12345